Work Here?
Merit Medical Systems
Work Here?
Manufactures disposable medical devices for interventions
Merit Medical Systems
Work Here?
Manufactures disposable medical devices for interventions
Overview
Company Does Not Provide H1B Sponsorship
Merit Medical Systems develops, manufactures, and distributes proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures across cardiology, radiology, oncology, critical care, and endoscopy. These one-time-use devices are used during procedures and supported by a global sales force and clinical team that provides training and support to hospitals. The company differentiates itself with a broad, multi-specialty product portfolio, an international footprint for manufacturing and distribution, and strong customer service and clinical support. Its goal is to transform patient care by delivering medical solutions that meet hospitals’ and patients’ needs worldwide.
About Merit Medical Systems
Industries
Industrial & Manufacturing
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
South Jordan, Utah
Founded
1987
Get referred to Merit Medical Systems
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $418.8 million, beating estimates and lifting full-year guidance on July 31.
- Non-GAAP EPS rose 18% to $1.19, while free cash flow neared $52 million.
- Sheri Lewis starts August 31, 2026, strengthening global operations after the COO elimination.
What critics are saying
- Merit faces $16 million 2026 tariff costs after Q2 refunds masked underlying pressure.
- View Point contributes only $2 million to $4 million revenue in 2026, but dilutes EPS.
- A tariff and supply-chain shock that destroys gross margin would expose Merit’s single-use device economics.
What makes Merit Medical Systems unique
- Merit’s 1,700-patent portfolio anchors interventional and therapeutic devices across recurring procedure workflows.
- View Point Medical adds OneMark oncology imaging, tripling Merit’s breast-biopsy addressable market on April 1, 2026.
- Cardiac Therapies and Endoscopy delivered 24% and 29% growth in Q2 2026.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$1.7B
Above
Industry Average
Funded Over
3 Rounds
Benefits
Health Insurance
Dental Insurance
Paid Vacation
Paid Sick Leave
Paid Holidays
401(k) Retirement Plan
Health Savings Account/Flexible Spending Account
Flexible Work Hours
Stock Price
Growth & Insights and Company News
6 month growth
↑ 12%1 year growth
↑ 12%2 year growth
↑ 14%Merit Medical Systems' shares have surged 22.2% over the past month following stronger second-quarter results and raised guidance. Revenue rose 9.5% year-over-year to $418.8 million, beating estimates by 3.5%. Adjusted earnings of $1.19 per share increased 18% and exceeded expectations by 23.9%. Therapeutic revenues drove growth, advancing 15%, with Cardiac Therapies and Endoscopy up 24% and 29% respectively. Adjusted gross margin expanded 260 basis points to 55.8%, supported by pricing and operational improvements. However, challenges persist. Tariff costs are expected to reach approximately $16 million in 2026, potentially limiting margin expansion. The stock now trades at 20.3 times forward earnings, above its sub-industry multiple of 17.6 times, suggesting much of the growth outlook may already be priced in.
Merit Medical Systems announced that Sheri Lewis will join as Executive Vice President of Global Operations on 31 August 2026. Lewis brings 30 years of experience in global operations, manufacturing, and supply chain management, having previously held senior positions at SkinHealth Systems, Avantor, Medtronic, and Honeywell. Lewis will replace Neil Peterson, who is transitioning to Senior Advisor to ensure continuity until 5 March 2027. Peterson has served Merit for over 32 years, including four years as Chief Operating Officer. Merit Medical, founded in 1987, manufactures medical devices for interventional, diagnostic, and therapeutic procedures. The company employs approximately 7,500 people worldwide.
Merit Medical Systems reported Q2 2026 revenue of $418.8 million, up 9.5% year-on-year and beating analyst estimates of $405.3 million. The medical device company's non-GAAP profit of $1.19 per share exceeded consensus by 24%. The strong performance was driven by recent acquisitions, including Biolife and the C2 CryoBalloon, alongside organic growth in core platforms like Vascular Intervention and Cardiac Therapies. CEO Martha Aronson noted the company achieved its strongest quarterly organic growth in three years. Merit Medical raised its full-year revenue guidance to $1.64 billion at the midpoint, up from $1.62 billion, and lifted adjusted EPS guidance to $4.30. Operating margin expanded to 14.4% from 12.3% year-on-year.
Merit Medical Systems reported second-quarter revenue of $418.8 million, up 10% year-over-year, driven by broad-based demand across its product portfolio. Organic constant-currency growth reached 9%, the company's strongest quarterly performance in three years. Non-GAAP earnings per share increased 18%, whilst free cash flow totalled nearly $52 million. US sales rose 12% to $26.1 million, and international sales grew 5% to $7.3 million. The BioLife acquisition is expected to generate approximately $23 million in annualised revenue for 2026. View Point Medical's OneMark system launched in the US, expanding Merit's oncology market opportunity. Merit raised its 2026 outlook, now expecting 6.9%–7.6% constant-currency revenue growth and non-GAAP EPS of $4.25–$4.35.
Merit Medical Systems reported second quarter 2026 revenue of $418.8 million, up 10% year-over-year. Constant currency revenue and constant currency revenue on an organic basis both grew 9%. The medical device manufacturer's GAAP operating margin improved to 14.4% from 12.3% in the prior year period. Non-GAAP operating margin reached 22.6%, compared to 21.2% previously. GAAP earnings per share rose 20% to $0.65, whilst non-GAAP EPS increased 18% to $1.19. Year-to-date cash flow from operations totalled $110.0 million, down 11%, and free cash flow was $76.6 million, down 14%. US sales grew 10% year-over-year, exceeding expectations. The company raised its full-year 2026 revenue and non-GAAP EPS guidance following the stronger first-half performance.
There are no jobs for Merit Medical Systems right now.
Find jobs on Simplify and start your career today
About Merit Medical Systems
Industries
Industrial & Manufacturing
Healthcare
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
South Jordan, Utah
Founded
1987
There are no jobs for Merit Medical Systems right now.
Find jobs on Simplify and start your career today